Ted Schwartz family gifts $15M to City of Hope to accelerate immunotherapy research

UCLA scientists identify clues to making immunotherapy more effective against glioblastoma

Two studies led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center provide insight into how the immune system can successfully be activated against glioblastoma while revealing why these therapies have historically fallen short.

October 16, 2026

Vol.52 No.38

Clinical Roundup

Wistar Institute study identifies immunotherapy strategy for glioblastoma

Scientists at the Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma. The researchers showed that reprogramming myeloid cells, a type of immune cell that glioblastoma tumors co-opt to protect themselves, while simultaneously boosting cancer-fighting T cells shrank the tumors and prevented them from coming back.

October 16, 2026

Vol.52 No.38

Clinical Roundup

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion

Researchers from City of Hope have developed a “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. The preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.

October 02, 2026

Vol.52 No.36

How biology is reshaping breast cancer care

Breast cancer treatment has changed dramatically over the past decade. One of the most important advances has been our growing ability to understand the biology of each patient’s cancer and use those insights to guide treatment decisions more precisely. That shift is helping make personalized cancer care a reality.

City of Hope blood test shows promise for detecting pancreatic cancer at its earliest stages

Researchers at City of Hopeled the development of a new, investigational blood test that could detect pancreatic cancer at its earliest stages, when the disease is more treatable and potentially curable.

September 18, 2026

Vol.52 No.34

Clinical Roundup

UT Austin study uncovers new driver of immunotherapy resistance in pancreatic cancer

Pancreatic tumors can resist immunotherapy by recruiting nearby immune cells to help protect them, according to researchers at The University of Texas at Austin. The findings, published in Nature Communications, also point to a potential new strategy for overcoming resistance and improving cellular therapies.

September 18, 2026

Vol.52 No.34

Ted Schwartz family gifts $15M to City of Hope to accelerate immunotherapy research

YOU MAY BE INTERESTED IN

UCLA scientists identify clues to making immunotherapy more effective against glioblastoma

Wistar Institute study identifies immunotherapy strategy for glioblastoma

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion

How biology is reshaping breast cancer care

City of Hope blood test shows promise for detecting pancreatic cancer at its earliest stages

UT Austin study uncovers new driver of immunotherapy resistance in pancreatic cancer

Renew today!

Subscriber content

Never miss an issue!

Login